Latest Regulatory Filings News

Sayona Mining’s merger with Piedmont Lithium faces further delay due to shareholder quorum shortfall, prompting an extension of its financing agreement with Resource Capital Fund VIII. The extension includes a potential AU$38 million capital injection through new options.

Life360, Inc. reported a return to profitability in Q2 2025, driven by strong subscription growth and strategic partnerships, while also announcing a leadership transition and issuing $320 million in convertible notes.

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

News Corporation has reported a modest 2% increase in revenues to US$8.452 billion for the fiscal year ended June 30, 2025, alongside a remarkable 344% surge in net income to US$1.18 billion. The company declared a stable total dividend of US$0.20 per share, reflecting confidence despite market challenges.

Key Petroleum has completed a $152,361 placement, issuing over 3.6 million shares to a sophisticated investor to support merger preparations and working capital needs.

The Supreme Court of New South Wales has approved DP World Australia’s acquisition of Silk Logistics, paving the way for a $2.14 per share cash payout to Silk shareholders and imminent suspension of Silk shares on the ASX.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

ChemX Materials Limited has explained the delayed filing of director interest notices, attributing it to transitional challenges during its recent recapitalisation and governance overhaul.

Unith Ltd has acknowledged a technical breach of its trading policy following a director's share purchase during a closed period, prompting a comprehensive review of its governance framework.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.

Alara Resources Limited has addressed an ASX query regarding the late filing of a director's interest notice, attributing the delay to complexities in share ownership disclosure. The company confirms existing compliance arrangements remain robust.